Placebo News and Research

RSS

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.

5 Feb 2013

ATI Neurostimulation System demonstrates clinical effectiveness in treating cluster headache

Autonomic Technologies, Inc. (ATI), the developer of the ATI Neurostimulation System designed for the treatment of severe headaches, today announced results of their clinical study in cluster headache, now published online in Cephalalgia.

5 Feb 2013

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that The Journal of Urology has electronically published the uncorrected proof of the pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials on its website.

5 Feb 2013

Indian medicines ‘promising’ for osteoarthritis care

Ayurvedic medicine may offer osteoarthritis relief, say Indian researchers who found traditional formulations to be equal to conventional drugs for the improvement of pain and knee function.

4 Feb 2013

Two new studies examine causes, treatment of severe malnutrition

"Two studies of malnourished children offer the first major new scientific findings in a decade about the causes and treatment of severe malnutrition, which affects more than 20 million children around the world and contributes to the deaths of more than a million a year," the New York Times reports.

2 Feb 2013

Book reviews psilocybin's potential in alleviating psychological distress in cancer patients

Improvements in the diagnosis and treatment of cancers in recent years have led to a marked increase in patients' physical survival rates. While doctors can treat the physical disease, what is not well understood is how best to address the psychological needs of patients with cancer.

1 Feb 2013

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

Disulfiram was the first medication approved for the treatment of alcoholism over 50 years ago. It works, at least in part, by preventing the metabolism of an alcohol by-product, acetaldehyde. High levels of acetaldehyde in the body quickly cause unpleasant symptoms, including nausea, vomiting, headache, and accelerated heart rate. Thus, disulfiram provides a very strong incentive to avoid drinking.

1 Feb 2013

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC (MET-high patients with tivantinib in HCC) trial of tivantinib (ARQ 197).

31 Jan 2013

Celsion's ThermoDox does not meet primary endpoint in Phase III HCC study

Celsion Corporation, a leading oncology drug development company, today announced that ThermoDox in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer.

31 Jan 2013

Top-line results from Vanda's tasimelteon Phase IIb/III study on major depressive disorder

Vanda Pharmaceuticals Inc. today announced top-line results of the Phase IIb/III clinical study (MAGELLAN) in Major Depressive Disorder (MDD), investigating the efficacy and safety of tasimelteon as a monotherapy in the treatment of patients with MDD.

31 Jan 2013

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

The U.S. Food and Drug Administration recently announced the authorization of FerriScan R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia.

31 Jan 2013

Positive results from PaxVax's Ad4-H5-Vtn vector vaccine Phase 1 trial on avian flu

PaxVax, Inc., which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced positive results in a Phase 1 clinical trial for its oral, replicating adenovirus serotype 4 (Ad4) vector vaccine for H5N1 (avian flu).

31 Jan 2013

Strong placebo response key to adolescent migraine trial failures

A strong response to placebo is the main reason drug trials in the treatment of adolescent migraine have so far failed, say researchers.

31 Jan 2013

Interferon retreatment of chronic hepatitis C may be harmful

People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are likely to experience a variety of adverse effects, according to an updated systematic review published in The Cochrane Library.

31 Jan 2013

Selenium supplements do not reduce risk of developing heart disease according to current evidence

A systematic review published today in The Cochrane Library finds that in well-nourished adults current evidence does not support selenium for preventing heart disease.

31 Jan 2013

Cerebrolysin: a promising new treatment for dementia

Dementia patients may benefit from a promising new treatment called Cerebrolysin, according to the results of a systematic review published in The Cochrane Library. The authors brought together the most up-to-date evidence on Cerebrolysin as a treatment for vascular dementia.

31 Jan 2013

No added benefit from linagliptin in patients with type 2 diabetes

Linagliptin has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes. The assessment of the new dossier according to the German Act on the Reform of the Market for Medicinal Products (AMNOG) again showed that no added benefit of the drug over the appropriate comparator therapy (ACT) can be determined, because the pharmaceutical company has not submitted any relevant studies.

31 Jan 2013

Mount Sinai to initiate immunological therapy trial against chronic pulmonary sarcoidosis

Patients are currently being enrolled in the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis. The trial is being conducted by researchers at the Icahn School of Medicine at Mount Sinai.

31 Jan 2013

No proof of added benefit from aclidinium bromide in adults with COPD

The drug aclidinium bromide has been approved since October 2012 for widening the narrowed airways of adults with chronic-obstructive pulmonary disease (COPD). The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG).

31 Jan 2013

No added benefit from perampanel in patients with epileptic fits

The drug perampanel has been approved since July 2012 as adjunctive therapy for adults and children aged 12 years and older with epileptic fits (seizures).

30 Jan 2013

Placebo News and Research

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

ATI Neurostimulation System demonstrates clinical effectiveness in treating cluster headache

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

Indian medicines ‘promising’ for osteoarthritis care

Two new studies examine causes, treatment of severe malnutrition

Book reviews psilocybin's potential in alleviating psychological distress in cancer patients

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

Celsion's ThermoDox does not meet primary endpoint in Phase III HCC study

Top-line results from Vanda's tasimelteon Phase IIb/III study on major depressive disorder

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

Positive results from PaxVax's Ad4-H5-Vtn vector vaccine Phase 1 trial on avian flu

Strong placebo response key to adolescent migraine trial failures

Interferon retreatment of chronic hepatitis C may be harmful

Selenium supplements do not reduce risk of developing heart disease according to current evidence

Cerebrolysin: a promising new treatment for dementia

No added benefit from linagliptin in patients with type 2 diabetes

Mount Sinai to initiate immunological therapy trial against chronic pulmonary sarcoidosis

No proof of added benefit from aclidinium bromide in adults with COPD

No added benefit from perampanel in patients with epileptic fits

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News